Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hims Hers Health

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three…

Benzinga

Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say

Shares of Hims Hers Health Inc (NYSE:HIMS) are under pressure Tuesday, after the company reported downbeat second-quarter revenues.

Benzinga

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Health Stock Tumbles On Q2 Earnings As Revenue Comes Up Short, Company Sees 'Exciting Period Of Growth' Ahead

Hims Hers Health Inc (NYSE:HIMS) reported second-quarter earnings after the market close on Monday. Here’s a rundown of the report.

Benzinga

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Benzinga

Hims & Hers Stock Could Rocket To Meme Stock Fame — If Short Sellers Feel The Squeeze

Hims Hers Health, Inc. (NYSE:HIMS) has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally.

Benzinga

What's Going On With Hims & Hers Stock Wednesday?

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.

Benzinga

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know.

Benzinga

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

International Business Times UK

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Benzinga

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

MarketBeat

Where Hims & Hers Health Stands With Analysts

Analysts' ratings for Hims Hers Health (NYSE:HIMS) over the last quarter vary from bullish to bearish, as provided by 10 analysts.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Hims Hers Health (NYSE:HIMS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big…

Fortune

Exclusive: The COO of Hims & Hers was the third person to try their GLP-1 drugs—and she's ready to share her story

Health executive Melissa Baird is dedicated to breaking the stigma of weight management at work.

Barchart

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Kiplinger

Stock Market Today: Stocks Rise as Fed Speakers Speak and Nvidia Awaits

Markets eked out gains in a low-volume session that was more focused on upcoming earnings from NVDA.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Upgrades

Benzinga

3 Stocks Under $5 Insiders Are Aggressively Buying

U.S. stocks closed sharply lower, with the Nasdaq Composite dipping around 450 on Thursday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

Benzinga

Earnings Preview For Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hims & Hers Health will report an earnings per share (EPS) of $-0.07.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.